Naoris is Spearheading the First Decentralized Post-Quantum Infrastructure for Web2, Web3 & Web 4WELLINGTON, FL, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Naoris Protocol, the first in production quantum-resistant blockchain and cybersecurity mesh architecture, has announced its upcoming TGE for July 31, 2025, marking a key milestone in the rollout of a new foundational security layer for the internet, designed to protect both Web3 and Web2 ecosystems from quantum and traditional threats. The $NAORIS token will launch for trading on July 31 at 12:00PM UTC / 08:00AM ET. At TGE, the initial circulating supply will be 599.260,000 NAORIS tokens, with a fully diluted valuation (FDV) of $500M FDV. The token will be available for trading on Binance Alpha, Binance Perps, and Gate.io with additional exchange listings to be confirmed. For the latest details, visit the Naoris Protocol website on July 31.In terms of utility, the $NAORIS token powers a machine-driven trust economy, enabling real-time, quantum-resistant security validations across both Web3 and traditional Web2 infrastructures. Embedded at the Sub-Zero layer within a Decentralized Trust Mesh, $NAORIS powers autonomous device-to-device security challenges that trigger token swaps per block, ensuring continuous, automated trust without human input. Each node earns influence and rewards based on its trust score, creating a dynamic consensus system rooted in behavior and reliability. Token holders can stake to secure the network and participate in governance, aligning incentives with long-term protocol resilience.The announcement comes just weeks after Naoris raised $3 million in a strategic funding round led by Mason Labs, with participation from Frekaz Group, Level One Robotics and Tradecraft Capital.The $NAORIS token is the core utility asset powering this infrastructure, enabling access to security services, governance and incentives for network participants. As the lifeblood of the Naoris Protocol, $NAORIS serves as the cyber-trust primitive that drives decentralized security infrastructure across blockchains, enterprises and IoT ecosystems.Operating at the Sub-Zero Layer, beneath L0 to L2 blockchains, Naoris Protocol provides the trust and security fabric for decentralized applications and existing internet infrastructure. It integrates directly with EVM-compatible blockchains without requiring hard forks and extends protection to blockchain transactions, physical infrastructure, including enterprise systems, cloud platforms, IoT devices, validators, bridges and decentralized exchanges. Naoris Protocol’s Post-Quantum technology is aligned with NIST, NATO and ETSI post-quantum standards – the US Government has mandated that all digital systems transition to post-quantum cryptographic standards by 2030, with legacy algorithms fully phased out by 2035.“At Naoris, we firmly believe that blockchains cannot retrofit their way to post-quantum security, they must be built into the infrastructure from the ground up,” said Naoris CEO and Founder David Carvalho. “Our TGE helps us move closer to delivering the next standard in cyber-resilient infrastructure,ensuring global systems remain secure in the post-quantum era.”Naoris’ architecture combines Post-Quantum Cryptography, Decentralized Proof-of-Security (dPoSec) consensus, and Swarm AI to secure blockchain transactions and web infrastructure against quantum computing risks. Key features include:Quantum-Secure Blockchain Transactions: Enhances EVM blockchains against quantum threats without network disruptions.Trusted Web3 Infrastructure: Immutable, real-time mesh network secures nodes, validators, bridges, and DEXs.Distributed Web2 Security: Converts all devices into validator nodes, forming a self-healing network without single points of failure.Since launching its testnet in January, Naoris Protocol has recorded significant growth, with over 100 million post-quantum transactions processed, over 3.3 million wallets onboarded, over 1M security nodes and over 475 million cyber threats mitigated as well as 31 active projects under development across sectors such as finance, telecom, energy, defense, and IoT.Alongside CEO and Founder David Carvalho, Naoris Protocol is guided by a leadership team with deep expertise across cybersecurity, defense, and blockchain verticals, bringing together a diverse range of global experience. The team includes David Holtzman, former CTO of IBM and a key architect of the DNS protocol; Ahmed Réda Chami, Ambassador of Morocco to the European Union and former CEO of Microsoft North Africa; Mick Mulvaney, former White House Chief of Staff; and Inge Kampenes, retired Major General and former Chief of the Norwegian Armed Forces Cyber Defence. Their combined backgrounds reflect the protocol’s focus on building secure, scalable infrastructure for both Web3 and traditional systems.To learn more about Naoris Protocol, users can visit https://www.naorisprotocol.com/ About Naoris ProtocolNaoris Protocol is the world’s first Decentralized Post-Quantum Infrastructure, built to secure both Web3 and Web2 against traditional and quantum threats. Operating beneath blockchain layers 0 to 3 as a Sub-Zero Layer, it integrates with existing EVM chains, nodes, bridges, dApps, enterprise systems, and IoT devices without requiring hard forks.Media Contact: sharon@babslabs.io  Disclaimer: All product and company names herein may be trademarks of their registered owners.  The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Copyright 2025 ACN Newswire via SeaPRwire.com.

HAYWARD, CALIFORNIA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - Biolog, a leading provider of microbial identification and phenotypic characterization tools and services, announced today that both its anaerobic media and anaerobic chambers have received CE marking, clearing the way for broader international use. The media and chambers were part of Biolog's acquisition of Anaerobe Systems earlier this year with the objective of bringing class-leading tools for microbiology to the rapidly growing clinical, microbiome, and agricultural markets.Today, Biolog's TruPRAS™ media is the only commercial media manufactured under true pre-reduced, anaerobically sterilized conditions, preventing the formation of harmful byproducts that can be toxic to anaerobic organisms. This line of media products, which has been approved for In Vitro Diagnostic (IVD) use by the USA FDA for years, has now also achieved CE marking under the requirements of the EU IVDR regulation 2017/746. With zero recalls or field actions throughout their extensive history, these products enable transport of specimens and growth of fastidious anaerobes that play important roles in disease pathology - supporting clinical diagnostics in medical laboratories."The IVDR/CE mark is a major milestone that recognizes the high standard of our anaerobic media and its value in supporting critical diagnostic workflows," said Robert Wicke, CEO at Biolog. "We're proud that clinical labs throughout Europe can now benefit from the same reliable performance that researchers and clinicians in the U.S. have trusted for decades."Biolog's anaerobic chambers have also received the CE mark, affirming their safety and performance for use in any research settings throughout the world. With unique InstaSleeve™ technology, these ergonomic, gloveless chambers offer superior processing dexterity while working in a fully anaerobic environment and are a preferred tool for microbiologists in both clinical and academic settings. In addition, Biolog is releasing an upgrade to enable hypoxic or microaerophilic conditions in the same chamber, for organisms that require specific, low concentrations of oxygen to thrive."This dual achievement reinforces Biolog's commitment to advancing global access to high-quality tools for anaerobic microbiology," said Wicke. "Whether you're working with challenging clinical isolates or conducting fundamental research, Biolog now provides dependable CE-marked solutions that meet your needs."About BiologBiolog offers tools, services, and support for comprehensive cellular characterization and multi-omic identification of bacteria, yeast, and fungi. Our products also enable phenotypic profiling of microbial and mammalian cells for a range of applications, including supporting the culture of fastidious anaerobes with our line of gloveless chambers and pre-reduced media. Learn more at biolog.comContact InformationJohn Proctor, Ph.D.CCOjproctor@biolog.com(408)306-0414SOURCE: Biolog, Inc. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - July 25, Guotai Junan International Holdings Limited (“GTJAI” or the “Company”, stock code: 1788.HK), a company of Guotai Haitong Group, is pleased to announce that while actively saving energy and reducing emissions，it has successfully offset its Scope 1 and Scope 2 carbon emissions totaling 609.29 tons of carbon dioxide equivalent for the year 2024 by subscribing to the carbon credits issued under the international Verified Carbon Standard (VCS). This marks the third consecutive year that GTJAI has achieved “carbon neutrality” at the operational level, demonstrating the Company's leading practice and commitment to green operation.The carbon credits come from “Guoluo Grassland Sustainable Management Project” located in Guoluo Tibetan Autonomous Prefecture, Qinghai Province, China. It is dedicated to the restoration of degraded grassland ecosystems, based on the holistic nature of the ecosystems, in line with the concept of ecological civilization construction, and to effectively respond to the challenges of climate change. The project is also the first grassland carbon project in China receiving both VCS certification and the Climate, Community and Biodiversity Standards (CCB) - CCB-Biodiversity Gold Level certification.In recent years, GTJAI has been continuously reducing its operational carbon footprint through systematic energy saving and emission reduction initiatives, which is the core support for the achievement of “carbon neutrality”, including vigorously implementing energy-saving renovation of office space, deepening digitalization and paperless transformation, and implementing stringent waste management (100% safe recycling of hazardous waste by 2024). Solid internal emission reduction efforts, combined with carbon offsetting through high-quality carbon credits, enabled the Company to achieve “carbon neutrality” at the operational level.Adhering to the core philosophy of “finance for the country, finance for the people, finance for the good”, GTJAI has always placed sustainable development at the core of its corporate strategy. The Company is committed to supporting the real economy through financial services while facilitating the green transformation of its corporate clients. In 2024, the Company successfully completed 90 sustainable finance projects covering green bonds, sustainable bonds and green sector IPOs with a total issuance volume of HK$179.8 billion, significantly broadening the financing pipeline for the green industry. Meanwhile, the private equity sector is actively engaged in the sustainability sector, with more than half of its investments focusing on ESG-related industries.Looking ahead, GTJAI will deepen the level of ESG governance, fully integrate ESG factors into its operations and management processes, further leverage its professional strengths and enhance the level of green financial services capabilities. Through innovative products and services, GTJAI will proactively contribute to the realization of the country's “dual carbon” goal and promote the high-quality development of the economy and society.About GTJAIGuotai Junan International (“GTJAI”, Stock Code: 1788.HK), a company of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes brokerage, corporate finance, asset management, loans and financing, financial products, which cover three dimensions including individual finance (wealth management), institutional finance (institutional investor services and corporate finance) and investment management. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “A” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 84% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH; 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com Copyright 2025 ACN Newswire via SeaPRwire.com.

ANKARA, Turkey, July 28, 2025 - (ACN Newswire via SeaPRwire.com) - GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, announced positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class and novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the Alzheimer's Association International Conference 2025 (AAIC®) in Toronto.This single oral ascending dose (SAD) Phase 1, first-in-human, randomized, double-blind, placebo-controlled study was conducted in three parts, involving a total of 53 healthy elderly adults. Part 1 included 6 cohorts (50, 100, 250, 500, 1000, and 2000 mg orally, n=23). In Part 2, the PK of a single 1000 mg oral dose was investigated in 10 healthy elderly adults. In Part 2B, the food effect was assessed using a randomized, single oral 2000 mg dose, two-treatment, two-period, crossover design (n=20).The trial results showed that single oral doses of 50-2000 mg of SUL-238 were safe and well-tolerated, while demonstrating a favourable PK profile and high cerebrospinal fluid (CSF) penetration. These findings make SUL-238 a promising candidate for further clinical development in neurodegenerative diseases, including Alzheimer's disease.No adverse effects (AEs) limited dose escalation, AE rates were comparable between SUL-238 and placebo, and all AEs were mild or moderate. The mean terminal elimination half-life was 0.86-3.80 hours, and the time to maximum plasma concentration was 0.50-1.39 hours. Under fed conditions, maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC0-∞) decreased by 50% and 60%, respectively. CSF-to-plasma percentages at 2 and 8 hours post-dose were 21.1% (±6.6%) and 74.2% (±46.0%).Abidin Gülmüs, Chairman of GEN, stated:"We are very encouraged by these promising first-in-human results, marking an important step forward in our mission to address the underlying biology of Alzheimer's disease."Nadir Ulu, MD, PhD, Vice President of R&D at GEN, added:"With its excellent safety and PK profile in this Phase 1 trial, combined with robust preclinical data, SUL-238 represents a strong candidate for further clinical development to meet the critical unmet needs in neurodegenerative diseases, including Alzheimer's disease."About SUL-238SUL-238 is a novel, first-in-class, hibernation-derived small molecule that targets mitochondria, the cell's "powerhouse." It supports mitochondrial bioenergetics via complex I/IV activation and has improved mitochondrial function in rodent models of neurodegenerative, cardiovascular, and renal diseases, as well as aging. SUL-238 crosses the blood-brain barrier and has undergone extensive safety evaluation in preclinical and Phase 1 studies. GEN licenses SUL-238 from Sulfateq BV for neurodegenerative disease applications.About GEN:Founded in 1998, GEN is Türkiye's leading specialty pharmaceutical company, focused on developing innovative therapies across multiple therapeutic areas. GEN manufactures high-quality, competitive products at its GMP-certified facility and pursues original drug development through two dedicated R&D centers and investments.About Sulfateq:Sulfateq B.V. is an early-stage Dutch biotech company that fosters strategic collaborations with academic and industrial research centers to accelerate the development of innovative new medicines. It has developed a novel class of small molecules, the SUL-compounds, that maintain mitochondrial health.For more information:www.genilac.com.trwww.sulfateqbv.comContact InformationBulutay GünesSr. Head of Corporate Brandb.gunes@genilac.comAli KetenciogluInvestor Relations Managera.ketencioglu@genilac.comKees van der GraafSulfateq CEOinfo@sulfateqbv.com Copyright 2025 ACN Newswire via SeaPRwire.com.

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - July 28, 2025) - Doubleview Gold Corp (TSXV: DBG) (OTCQB: DBLVF) (WKN: LA1W038) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to announce the commencement of an advanced exploration program at its 90%-owned copper-silver-zinc-gold Red Spring Project, located in central British Columbia, Canada. This initiative marks a significant step in unlocking the project's full potential and reinforces Doubleview's commitment to critical mineral development.Red Spring Project: Inaugural 3D IP Survey UnderwayThe Red Spring Project, a pillar in Doubleview's expanding portfolio, is situated in a highly prospective region of central British Columbia, Canada. The Company holds a 90% interest in this compelling copper-silver-zinc-gold project, which has demonstrated strong mineralization in historical drilling, particularly in its central zone. Decades of previous operator activities, including sampling, geophysical surveys, and approximately 4,000 feet of drilling, have laid the groundwork for Doubleview's current advanced exploration. The project is strategically important to the Company as it strengthens its emphasis on critical minerals.The first phase of Doubleview's 2025 exploration program at the Red Spring property comprises an inaugural 3D Induced Polarization (IP) survey. This state-of-the-art three-dimensional geophysical survey will target the Angus Zone, an area of high interest previously sampled and prospected by the Company. The survey is expected to be completed by the end of August 2025.The 3D IP survey will provide valuable insights into the subsurface geology and will contribute to planning and guiding future drill programs. Farshad Shirvani, President and CEO of Doubleview Gold Corp, commented: "Due to significant third-party interest in the Company's flagship HAT project, management is strategically advancing exploration at its Red Spring Project, as it has consistently demonstrated strong potential, both historically and through Doubleview's past exploration efforts. The 3D IP program will provide detailed information and valuable insights with minimal environmental impact. Our goal is to gain a better understanding of the deposit, expand the area of interest, and help define precise targets for further work, including drilling. The Red Spring Project is an important component in Doubleview's portfolio of properties and emphasizes our focus on critical minerals."Doubleview is dedicated to collaborative engagement with local stakeholders and First Nations and strives to apply sustainable exploration methods that ensure minimal land impact.Hat Polymetallic Deposit UpdateExploration and definition of Doubleview's flagship Hat Project continues with 2025 drilling surpassing 6,500 meters. Drill hole H099, currently in progress, is approaching the significant 100 drill hole milestone. The preliminary economic assessment (PEA), metallurgy, and environmental baseline studies are continuing and underscore the comprehensive advancement of this significant polymetallic deposit.About Doubleview Gold Corp With active programs at both the HAT and Red Spring projects, Doubleview anticipates that 2025 will be its most productive year to date, reflecting the Company's robust and exciting exploration and development activities.Doubleview Gold Corp, trading on the TSX-Venture Exchange (TSXV: DBG) (OTCQB: DBLVF) (WKN: LA1W038) (FSE: 1D4) is a Canadian-based mineral resource exploration and development company focused on the discovery and advancement of high-value mineral deposits in British Columbia. The Company controls a portfolio of prospective mineral properties, including the Hat polymetallic deposit and the Red Spring copper-gold-silver project.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive Officer For further information please contact: Doubleview Gold Corp Vancouver, BC Farshad Shirvani President & CEO T: (604) 678-9587E: corporate@doubleview.caWebsite: www.doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Certain of the statements made and information contained herein may constitute "forward-looking information". In particular references to the private placement and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/260280 Copyright 2025 ACN Newswire via SeaPRwire.com.

Tokyo, Japan, July 28, 2025 - (ACN Newswire via SeaPRwire.com) -  Quantum Solutions Co., Ltd. (2338.T) and its affiliates (the “Quantum Solutions’ Group” or “Quantum Solutions”), a Tokyo Stock Exchange-listed company, today announced a new strategic milestone in its digital asset initiative. The Quantum Solutions’ Group, has entered into a business collaboration arrangement with TDX Strategies Ltd, a renowned digital asset technology company in Asia. The two parties will cooperate extensively in areas including Bitcoin trade execution, asset custody, structured product design, and market risk management—offering end-to-end technical and service support for Quantum Solutions’ Bitcoin Treasury strategy.Quantum Solutions previously disclosed its plan to accumulate up to 3,000 Bitcoins over the next 12 months, aiming to hedge inflation risks, optimize asset structure, and enhance the agility of its financial system. The collaboration with TDX Strategies marks a key transition from capital planning to systemized execution and is expected to substantially strengthen the Quantum Solutions’ technical capabilities and operational security in the management of digital assets.TDX Strategies is a tech-driven enterprise focused on trading and structuring of digital financial products. It holds licensed investment trading and operational status in the British Virgin Islands (BVI). With a strong track record in blockchain asset operations and a robust institutional network across markets, TDX serves a range of Asian family offices, asset managers, and corporate clients. For this collaboration, Quantum Solutions’ Group agrees to prioritize the selection of TDX’s paid cryptocurrency services on a non-exclusive basis, ensuring operational flexibility and execution reliability for the Treasury business.According to the agreement, TDX Strategies will provide comprehensive support to Quantum Solutions’ BTC Treasury business, including: assisting in the development of an institutional-grade trade execution system tailored for Bitcoin; establishing enterprise-level cold/hot wallet management frameworks and multi-signature security protocols to safeguard custody; designing principal-protected and yield-enhancing structured products based on Bitcoin holdings to improve capital efficiency; and delivering ongoing consulting in operational, technical, risk exposure control, and market response strategies.TDX Strategies is recognized as a next-generation digital asset firm with hands-on expertise in structured finance instruments, institutional trading infrastructure, and cross-chain solutions. Its team combines deep knowledge in blockchain application development and traditional risk management, and the company enjoys a strong reputation in the Asian crypto-financial space. Notably, TDX is one of the portfolio companies under a strategic partner of Quantum Solutions Mr. Tak Cheung Yam, the ultimate beneficial majority shareholder of renowned American media Forbes Media LLC a .Mr. Yam is also the sole owner of Integrated Asset Management (Asia) Limited, which recently extended a USD 10 million loan to Quantum Solutions’ Group to support the initial phase of its Bitcoin Treasury initiative. As a globally respected investor, Mr. Yam has committed both capital and infrastructure to accelerate Quantum Solutions’ entry into the digital asset space. Through this partnership, TDX Strategies’ technological resources and professional team have also been made available to Quantum Solutions, reflecting Mr. Yam’s full-spectrum commitment—both financially and operationally.Quantum Solutions noted that the collaboration establishes a comprehensive support system for its digital asset strategy—spanning funding, infrastructure, and compliance. This creates a closed-loop model from capital infusion to asset management, and represents a clear shift from “reserve asset” to “strategic asset” status for Bitcoin within the company’s evolving financial framework. The initiative is designed to deepen the asset’s integration into the corporate finance structure while maximizing its intrinsic and strategic value.Looking ahead, Quantum Solutions and TDX intend to expand their collaboration to cover a wider range of use cases, including Bitcoin yield strategies, stablecoin allocations, and cross-chain structured product development. These efforts aim to further enhance the flexibility and compounded value potential of the company’s digital asset portfolio.This partnership marks not only the operational execution of the company’s digital asset strategy, but also a significant step forward in building a future-ready financial architecture. As the Bitcoin Treasury program advances, Quantum Solutions expects to accelerate the development of an enterprise-grade reserve framework that is institutionalized, auditable, and responsive to market conditions—providing robust safeguards for long-term asset security and corporate growth.About Quantum Solutions Co., Ltd.Quantum Solutions Co., Ltd. (Tokyo Stock Exchange: 2338.T) is a Tokyo-based high-growth technology company specializing in artificial intelligence, big data analytics, and blockchain-related innovation. Founded in 2004 and listed on the Tokyo Stock Exchange, the company delivers advanced technology solutions across a range of industries, including fintech, healthcare, and smart manufacturing. In its financial year ended 28 February 2025, Quantum Solutions reported approximately USD 4.7 million in revenue and is currently holdings over several trademarks and patents in games. For more information, please visit: https://www.quantum-s.co.jp/en/corporateForward-Looking StatementsThis press release contains forward-looking statements based on information currently available to the company and certain assumptions regarding future events and expectations. These statements are subject to various risks and uncertainties—including but not limited to changes in policy, market conditions, technological developments, and regulatory factors—that could cause actual results to differ materially from those expressed or implied in such statements. Existing and prospective investors are advised to consider potential risks carefully and not to place undue reliance on any forward-looking statements contained herein. Such statements speak only as of the date of this release. Unless required by law, the company undertakes no obligation to update or revise any forward-looking statements in light of new information, future events, or other circumstances.For further enquiries, please contact:Hong Kong/International:Mr. Steven TungEmail: steven.tung@quantum-s.co.jpJapan:Ms. Linda PengEmail: linda.peng@quantum-s.co.jp Copyright 2025 ACN Newswire via SeaPRwire.com.

SHENZHEN, CHINA, July 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that on 28 July 2025, the New Drug Application (NDA) for improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) (“ZUNVEYL” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). The Product is indicated for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.About Product ZUNVEYLZUNVEYL was approved in July 2024 by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults. As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. With such a mechanism of action, ZUNVEYL is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long-term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001[1]. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed[2]. As the second oral therapy approved by FDA for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better gastrointestinal safety profile to improve compliance of Alzheimer’s disease patients and therefore brings clinical benefits. Patent in regard to use of ZUNVEYL has already been granted in China.About Alzheimer’s DiseaseAlzheimer’s disease is a chronic, progressive neurodegenerative disease characterized by progressive decline in memory and other cognitive functions, among which some of the patients will progress to dementia. Dementia is a kind of syndrome with acquired cognitive function impairment as the core symptom, and can lead to the reduction of patients’ daily living, learning, working and social interaction ability. Alzheimer dementia accounts for 50% to 70% of all types of dementia[3,4]. According to the epidemiological study results published in the Lancet Public Health[5], there are about 9.83 million patients with Alzheimer dementia in China, of which 7.93 million are mild-to-moderate[6]. With the intensifying aging trend, the number of patients and the consequent disease burden will further increase in the future.Currently the clinical treatment of Alzheimer’s disease can be categorized as improving cognitive symptoms and decelerating disease progression[7], and AChEI belongs to the former. According to the Research Report on the Diagnosis and Treatment of Alzheimer’s disease Patients in China[8], the high incidence of side effects is one of the major pain points for existing drugs for Alzheimer’s disease, and drug intolerance is one of the challenges in current treatment of Alzheimer’s disease. Tolerability affects therapy adherence, with data showing that 55% of Alzheimer’s disease patients discontinue their medication after one year, mainly due to GI side effects and insomnia. Medication discontinuation can cause risk to patients themselves, and dissatisfaction and burden among patient’s family, physicians, and caregivers[9]. Therefore, Alzheimer’s disease patients still have an urgent need for safer therapies.On 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement (the “Agreement”)  with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type. In accordance with the Agreement, the Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan and the Middle East region), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years (the “Initial Term”), it may be automatically renewed every five years upon the expiration of the Initial Term unless terminated by notice from either party.Around six months after obtaining the above rights of ZUNVEYL, the Group promptly submitted the NDA in China, demonstrating its efficient allocation of resources and robust capabilities in registration promotion. ZUNVEYL will further diversify the Group’s innovative drug product matrix and enhance the Group’s comprehensive competitiveness. The Product will synergize with the Group’s various central nervous system products including the innovative drug VALTOCO (diazepam nasal spray) and the original brand drug Deanxit (flupentixol and melitracen tablets) on sale and the innovative drug Y-3 for Injection under development in terms of expert network and market resources. Relying on the Group’s successful commercialization experience and compliant and efficient commercialization system, if ZUNVEYL is approved for marketing, it will bring a new drug option for the treatment of cognitive impairment in Chinese Alzheimer’s disease patients, meeting the clinical need for drugs of both efficacy and safety, improving disease diagnosis and treatment practices, thereby benefiting patients. The Product is expected to have a positive impact on the Group’s financial results.Reference:1. Xu, Hong et al. Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality. Neurology vol. 96,17 (2021): e2220-e2230. doi:10.1212/WNL.00000000000118322. Safety profile of ZUNVEYL as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease- 3. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 1): Dementia Classification and Diagnostic Criteria [J]. National Medical Journal of China, 2018, 98 (13): 965-970. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0034. 2018 Chinese Guidelines for the Diagnosis and Treatment of Dementia and Cognitive Impairment (Chapter 2): Guidelines For Diagnosis and Treatment of Alzheimer's Disease [J]. National Medical Journal of China, 2018,98 (13): 971-977. DOI: 10.3760/cma.j.issn.0376-2491.2018.13.0045. Jia, Longfei et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. The Lancet. Public health vol. 5,12 (2020): e661-e671. doi:10.1016/S2468-2667(20)30185-76. Yuan, Jing et al. Severity Distribution of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in the Framingham Heart Study. 1 Jan. 2021: 807-817.7. Mayo Clinic. 2024. Alzheimer’s Disease: Therapies to Improve Cognitive Symptoms and Decelerate Disease Progression. https://www.mayoclinic.org/zh-hans/diseases-conditions/alzheimers-disease/in-depth/alzheimers/art-200481038. Research Report on the Diagnosis and Treatment of Alzheimer’s Disease Patients in China (2020). Alzheimer's Disease Chinese (ADC). https://www.adc.org.cn/index.php/book/chinaadzlxzbg2020/chinaadzlxzbg2020-381.html9. Data on patient discontinuation as disclosed by Alpha:  https://www.alphacognition.com/investors/news/alpha-cognitions-oral-therapy-zunveyl-receives-fda-approval-to-treat-alzheimers-disease-About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in Southeast Asia and the Middle East regions, further escorting the sustainable and healthy development.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com.